Another failure in phase III clinical testing has finally sent the investigational Alzheimer's drug dimebon towards the trash heap, based on its commercial sponsors.
Pfizer and Medivation, the businesses co-developing the drug, introduced Tuesday that they are preventing all development activities following the phase III CONCERT trial unsuccessful to show significant benefit in patients with mild to moderate Alzheimer's.
The businesses will also be terminating a wide open-label extension study that adopted the primary trial, which in fact had randomized 1,003 patients to get dimebon or placebo additionally to Aricept for just one year.
Look at this story on world wide web.medpagetoday.com.
A phase III trial known as CONNECTION carried out 2010 had also unsuccessful to exhibit an advantage for dimebon.
The 2 negative tests offset favorable results observed in an early on phase III trial reported in 2008.
Dimebon came from in Russia decades ago, where it had been lengthy offered being an antihistamine for nasal congestion, resulting in findings of apparent benefit in Alzheimer's patients. The drug never was approved or offered within the U.S.
Pfizer and Medivation guaranteed that full is a result of CONCERT could be posted for presentation in a future scientific meeting.
No comments:
Post a Comment